Kathryn Guarini insider trades: Regeneron Pharmaceuticals (REGN) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kathryn reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | REGN | ↓ Sell | 400 | $900.00 | $360K | Direct | Nov 3, 2026 (4d) |
| Sep 2, 2026 | REGN | ↓ Sell | 400 | $850.00 | $340K | Direct | Sep 3, 2026 (1d) |
| Aug 10, 2026 | REGN | ↓ Sell | 400 | $800.00 | $320K | Direct | Aug 12, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other REGN insiders
Open-market trades in the last 12 months
About Kathryn Guarini's insider trades
Kathryn Guarini is a director at Regeneron Pharmaceuticals (REGN). Since Aug 10, 2026, Kathryn has reported no open-market purchases and 3 sales worth $1.0M on SEC Form 4. In the last 12 months: 3 sales ($1.0M).
Their filings also include grants and awards (4 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every REGN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.